Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAloha Care step therapy Coverage & Prior Auth | Op…
    Ask Trek AI about this page
    CurrentAloha CarePolicy N/A

    2026 AlohaCare Advantage Plus (HMO D-SNP) Drugs with Step Therapy Requirements

    Customize your policy alerts

    Sign up for all Aloha Care policy alerts

    Know when Aloha Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists Aloha Care Advantage Plus (HMO D-SNP) drugs that require trial of preferred therapies (step therapy) before coverage of other listed drugs; applies to prescribers and pharmacy prior authorization reviewers under this plan.

    Policy Summary
    PayerAloha Care
    PolicyDrugs with Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionDocument a trial of the specified preferred therapy (e.g., one generic carbidopa/levodopa for Rytary) when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8+drug groups or entries
    Rytary / Zonisadeproducts listed
    1explicit step rules
    2026-06-01effective

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage and Step Therapy Criteria

    Step therapy coverage criteria

    Covered when the specified prior therapy trials are documented

    Actinic keratosis - Diclofenac 3%: Trial of either topical fluorouracil OR topical imiquimod1 trial

    From chunk 4

    Antidepressants - Emsam/Exxua/Fetzima: Trial of two generics from specified list (bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine HCl) OR continuation of prior therapy2 trials

    From chunk 7

    Atypical antipsychotics - Fanapt et al: Trial of two of the listed oral generic atypical antipsychotics (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) OR continuation of prior therapy2 trials

    From chunk 10

    Invega Hafyera: Trial of one of Invega Sustenna OR Invega Trinza for new starts; continuation of prior therapy is approved1 trial

    From chunk 13

    Relistor: Trial of lubiprostone OR Constulose OR Enulose OR Generlac OR lactulose1 trial

    From chunk 16

    Rytary: Trial of one generic carbidopa/levodopa containing formulation1 trial

    From chunk 19

    Rytary - Initial Step Requirement

    Covered when ALL of the following are met

    Rytary initial step: Trial of one generic carbidopa/levodopa containing formulation1 trial

    applies as step therapy prior to Rytary

    Zonisade - Initial Step Requirement

    Covered when ALL of the following are met

    Zonisade initial step: Trial of generic zonisamide capsule1 trial

    Step applies to new starts only; continuation of prior therapy should be approved

    The step therapy requirement for Zonisade applies only to new starts. For initial therapy, the member must have a documented trial of a generic zonisamide capsule (1 trial) before Zonisade will be approved. Requests to continue therapy for members already receiving Zonisade should be approved without requiring the step trial.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior auth: Diclofenac 3% — document topical alternative trial

    Prior authorization requires documentation that the member has previously tried either topical fluorouracil or topical imiquimod before Diclofenac Sodium GEL 3% will be approved.

    • Step therapy requirement: trial of either topical fluorouracil OR topical imiquimod must be documented.
    Prior Authorization

    Prior auth: Branded antidepressants — document two generic trials

    Prior authorization requires documentation of trials of two generic antidepressant formulary products from the specified list (bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine HCl) before covering listed branded antidepressants; continuation of prior therapy is approved.

    • Document two trials from the enumerated generic antidepressants.
    • Continuation of prior therapy for listed products may be approved.
    Prior Authorization

    Prior auth: Atypical antipsychotics — document two generic trials

    Prior authorization requires documentation of trials of two oral generic formulary atypical antipsychotics (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) before Fanapt, Lybalvi, or Secuado will be approved; continuation of prior therapy is approved.

    • Document trials of two of the listed generic atypical antipsychotics.
    • Continuation of prior therapy for these products may be approved.
    Prior Authorization

    Prior auth: Invega Hafyera — trial of Sustenna or Trinza for new starts

    For new starts of Invega Hafyera, prior authorization requires documentation of a trial of Invega Sustenna or Invega Trinza; continuation of existing therapy should be approved.

    • Step applies to new starts only: document trial of Invega Sustenna OR Invega Trinza.
    • Approve continuation for members already on therapy.
    Prior Authorization

    Prior auth: Relistor — document trial of listed laxatives

    Prior authorization requires documentation of a trial of one of the listed laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) before Relistor will be approved.

    • Document trial of lubiprostone OR Constulose OR Enulose OR Generlac OR lactulose prior to Relistor.
    Prior Authorization

    Prior auth: Rytary — document generic carbidopa/levodopa trial

    Prior authorization requires documentation that the member tried one generic carbidopa/levodopa containing formulation before Rytary will be approved.

    • Document trial of one generic carbidopa/levodopa formulation prior to Rytary.
    Prior Authorization

    Step therapy prior auth — document required step trials

    Prior authorization decisions require documentation that the specified step therapy trial(s) of preferred generic alternatives were completed before approving the branded products; for Zonisade continuation requests, members already on therapy should be approved.

    • Document the exact step trial(s) specified for the product (e.g., generic alternatives listed per drug).
    • Continuation requests for members already on Zonisade should be approved.
    Step Therapy

    Step: Actinic keratosis — trial of fluorouracil or imiquimod required

    Step therapy requires a documented trial of either topical fluorouracil or topical imiquimod before Diclofenac Sodium GEL 3% is covered.

    • Document trial of either topical fluorouracil OR topical imiquimod for actinic keratosis prior to diclofenac gel 3%.
    Step Therapy

    Step: Antidepressants — two generic trials required

    Step therapy requires documentation of trials of two generics from the specified antidepressant list before covering the listed branded antidepressants; continuation of prior therapy is acceptable.

    • Trials must be from the enumerated generics: bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine HCl.
    • Continuation of prior therapy for listed products may be approved.
    Step Therapy

    Step: Atypical antipsychotics — two generic trials required

    Step therapy requires documentation of trials of two listed oral generic atypical antipsychotics (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) before Fanapt, Lybalvi, or Secuado; continuation of prior therapy is acceptable.

    • Document trials of two of the listed generics.
    • Continuation of prior therapy for these products may be approved.
    Step Therapy

    Step: Invega Hafyera — trial of Sustenna or Trinza for new starts

    For new starts of Invega Hafyera, step therapy requires a trial of Invega Sustenna or Invega Trinza; continuation of prior therapy is allowed.

    • Step applies to new starts only: document trial of Invega Sustenna OR Invega Trinza.
    • Approve continuation of prior therapy for existing users.
    Step Therapy

    Step: Relistor — trial of listed laxatives required

    Step therapy requires a documented trial of one of the listed laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) before Relistor is covered.

    • Document trial of lubiprostone OR Constulose OR Enulose OR Generlac OR lactulose prior to Relistor.
    Step Therapy

    Step: Rytary — trial of generic carbidopa/levodopa required

    Step therapy requires a documented trial of one generic carbidopa/levodopa containing formulation before Rytary is covered.

    • Document trial of one generic carbidopa/levodopa formulation prior to Rytary.
    Step Therapy

    Rytary step — trial of generic carbidopa/levodopa formulation

    Restatement: the Rytary step specifically requires a trial of one generic carbidopa/levodopa formulation prior to approval of Rytary.

    • Failure to meet this trial may lead to denial (see denial risk).
    Step Therapy

    Step: Zonisade — trial of generic zonisamide capsule for new starts

    Step therapy for Zonisade requires a documented trial of a generic zonisamide capsule for new starts only; approve continuation of prior therapy for members already receiving Zonisade.

    • Step applies to new starts only: document trial of a generic zonisamide capsule.
    • Continuation of prior therapy for existing members should be approved.
    Documentation Required

    Documentation: Actinic keratosis — record trial of fluorouracil or imiquimod

    Document the member’s trial of either topical fluorouracil or topical imiquimod before approving Diclofenac Sodium GEL 3% for actinic keratosis.

    • Include documentation showing use of topical fluorouracil OR topical imiquimod prior to diclofenac gel 3%.
    Documentation Required

    Documentation: Antidepressants — record two generic trials or prior therapy

    Document trials of two generics from the specified antidepressant list, or document continuation of prior therapy when applicable, before approving the listed branded antidepressants.

    • Record which two generic antidepressants from the enumerated list were tried and dates/duration.
    • If continuing prior therapy, document existing therapy details.
    Documentation Required

    Documentation: Atypical antipsychotics — record two generic trials or prior therapy

    Document trials of two generic atypical antipsychotics from the specified list, or document continuation of prior therapy, before approving Fanapt, Lybalvi, or Secuado.

    • Record which two generic atypical antipsychotics were tried and dates/duration.
    • If continuing prior therapy, document existing therapy details.
    Documentation Required

    Documentation: Invega Hafyera — record trial for new starts or prior therapy for continuation

    For Invega Hafyera new starts, document trial of Invega Sustenna or Invega Trinza; for continuation requests, document existing prior therapy to support approval.

    • Document trial of Invega Sustenna OR Invega Trinza for new starts.
    • For continuation, document prior therapy details to allow approval.
    Documentation Required

    Documentation: Relistor — record trial of listed laxatives

    Document trial of one of the listed laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) before approving Relistor.

    • Record which laxative was tried and dates/duration prior to Relistor.
    Documentation Required

    Documentation: Rytary — record generic carbidopa/levodopa trial

    Document a trial of one generic carbidopa/levodopa containing formulation prior to approving Rytary; supporting documentation of the trial is required to meet step therapy criteria.

    • Record which generic carbidopa/levodopa formulation was tried and dates/duration.
    • Lack of this documentation may result in denial.
    Documentation Required

    Required supporting documentation — record the specified trial per plan

    Documented trial evidence as specified in each product’s step requirement (for example, the named generic alternative or formulation) is required to meet step therapy criteria for approval.

    • Provide documentation matching the plan’s stated trial requirement (e.g., generic carbidopa/levodopa formulation; generic zonisamide capsule).
    • Ensure dates and duration of trials are included.
    Denial Risk

    Denial risk: failure to document step therapy trials

    Coverage of listed drugs may be denied if the required prior trial(s) of preferred agents (step therapy) are not documented.

    • Failure to provide required step trial documentation can result in denial of coverage.
    Denial Risk

    Denial risk: Rytary — missing generic carbidopa/levodopa trial

    Failure to document a trial of one generic carbidopa/levodopa formulation as required may trigger denial for Rytary prior authorization or step therapy requests.

    • Ensure documentation of the specified generic carbidopa/levodopa trial to avoid denial.
    Denial Risk

    Denial risk: Zonisade — missing generic zonisamide trial for new starts

    For new starts of Zonisade, lack of documented trial of a generic zonisamide capsule may trigger denial; continuation requests for members already on therapy should be approved.

    • New starts: document trial of a generic zonisamide capsule to meet step requirement.
    • Continuation: approve when prior therapy is documented.

    Key Definitions

    Step therapy
    DefinitionStep therapy: requirement to trial a specified generic alternative formulation prior to coverage of the listed product.
    Action requiredTrial of one generic carbidopa/levodopa containing formulation is required prior to coverage of Rytary (step = 1).
    Zonisade requirementTrial of a generic zonisamide capsule is required for new starts of Zonisade; continuation of prior therapy should be approved.
    ApplicabilityStep therapy applies to initial (new) starts; continuation of therapy for members already on the drug is approved where specified.
    DocumentationProviders must document the required prior trial(s) of the specified generic formulation(s) to meet step therapy criteria.

    Initial (New Start) Therapy Requirements

    Initial therapy requirements

    Initial therapy (new starts) require documented trials of preferred agents as specified below.

    Diclofenac 3% initial: Trial of either topical fluorouracil OR topical imiquimod before approval

    From chunk 4

    Emsam/Exxua/Fetzima initial: Trial of two generics from specified antidepressant list before approval

    From chunk 7

    Fanapt/Lybalvi/Secuado initial: Trial of two listed generic atypical antipsychotics before approval

    From chunk 10

    Invega Hafyera initial: Trial of Invega Sustenna OR Invega Trinza for new starts

    From chunk 13

    Relistor initial: Trial of listed laxatives (lubiprostone, Constulose, Enulose, Generlac, OR lactulose) before approval

    From chunk 16

    Rytary initial: Trial of one generic carbidopa/levodopa formulation before approval

    From chunk 19

    Initial therapy steps

    Initial therapy step requirements for listed drugs

    Rytary initial: Trial of one generic carbidopa/levodopa containing formulation required for new starts1 trial

    From chunk 19

    Zonisade initial: Trial of generic zonisamide capsule required for new starts1 trial

    From chunk 22

    Continuation of Therapy Rules

    Continuation therapy rules

    Continuation of prior therapy is allowed for certain products listed.

    Antidepressants continuation: Approve continuation of prior therapy for Emsam, Exxua, Fetzima products

    From chunk 7

    Atypical antipsychotics continuation: Approve continuation of prior therapy for Fanapt, Lybalvi, Secuado

    From chunk 10

    Invega Hafyera continuation: Approve continuation of prior therapy; step applies to new starts only

    From chunk 13

    Zonisade continuation

    Continuation of prior therapy

    Zonisade continuation: Approve continuation of prior therapy for members already on ZonisadeN/A

    Step applies to new starts only

    Step Therapy Matrix

    Drug / IndicationStep requirementCoverage stance
    Diclofenac sodium gel 3% (Actinic keratosis)Trial of either topical fluorouracil OR topical imiquimodcovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Emsam, Exxua, Exxua Titration Pack, Fetzima, Fetzima Titration Pack (Antidepressants)Trial of two generics from the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride; OR approve for continuation of prior therapycovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Fanapt, Fanapt Titration Pack C, Lybalvi, Secuado (Atypical antipsychotics)Trial of two of the following oral generic atypical antipsychotics: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone; OR approve for continuation of prior therapycovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Invega Hafyera (long-acting injectable antipsychotic)Trial of one of the following: Invega Sustenna OR Invega Trinza; step applies to new starts only; approve continuation of prior therapycovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Relistor (opioid-induced constipation / constipation agents)Trial of one of the following laxatives: lubiprostone OR Constulose OR Enulose OR Generlac OR lactulosecovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Rytary (carbidopa/levodopa, Parkinson's disease)Trial of one generic carbidopa/levodopa containing formulationcovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Rytary (carbidopa/levodopa, Parkinson's disease)Trial of one generic carbidopa/levodopa formulation prior to Rytarycovered_with_criteria
    Drug / IndicationStep requirementCoverage stance
    Zonisade (zonisamide)Trial of a generic zonisamide capsule; step applies to new starts only; approve continuation of prior therapycovered_with_criteria
    Policy Summary
    PayerAloha Care
    PolicyDrugs with Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionDocument a trial of the specified preferred therapy (e.g., one generic carbidopa/levodopa for Rytary) when requesting prior authorization.
    SourceLink
    On This Page
    Coverage and Step Therapy CriteriaPrior Authorization and Documentation RequirementsKey DefinitionsInitial (New Start) Therapy RequirementsContinuation of Therapy RulesStep Therapy Matrix